Why is SELLAS Life Sciences Group (SLS) stock down today?

SELLAS Life Sciences Group shares fell 5.42% to $12.47 on July 20, 2026, swinging sharply from a day range of $11.88 to $13.58, as early momentum faded after a period of dramatic gains. The retreat appears to be profit-taking following a speculative surge: the stock had risen roughly 21% in recent days and is up approximately 550% over the past year, fueled entirely by clinical-trial expectations — the company currently has no revenue.

The core catalyst driving recent volatility is the Phase 3 REGAL trial, which is evaluating GPS (galinpepimut-S, a cancer immunotherapy) in patients with acute myeloid leukemia (AML) who achieve remission but are not eligible for a stem cell transplant. The trial has reached 78 of the 80 patient-death events required to trigger the final statistical analysis, meaning a topline readout is imminent. That nearness has attracted speculative traders betting on a positive result — and potentially on interest from large pharmaceutical companies looking to acquire a successful late-stage asset.

Retail and options traders rallied in prior sessions around two additional catalysts: a newly disclosed institutional position by Armstrong Advisory Group (380 shares worth about $5,610 — notable mainly as a signal of fresh institutional attention, not its size) and CNBC personality Jim Cramer calling SELLAS 'a great spec' and giving the stock 'two thumbs up' on Mad Money's Lightning Round. The CEO also appeared on Fox, with retail investors speculating that a positive AML readout could spark a Big Pharma bidding war. These sentiment-driven moves are characteristic of pre-readout biotech trading.

The broader market provided little directional cover: the S&P 500 (tracked by the SPY ETF) was down just 0.19% and the Nasdaq-100 (QQQ) was essentially flat at +0.10%, so today's SLS decline is specific to the stock, not a sector-wide selloff. With no macro events on the calendar this week, all eyes for SLS remain on the REGAL trial result.

SELLAS carries a market cap of approximately $2.32 billion despite generating zero revenue last quarter — a valuation driven entirely by the binary outcome of the REGAL readout. The stock sits in a high-volatility, pre-catalyst state: it surged on speculation and is now giving back some of those gains ahead of a result that has not yet been announced.